Cargando…
Pharmacotherapy alleviates pathological changes in human direct reprogrammed neuronal cell model of myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is a trinucleotide repeat disorder affecting multiple organs. However, most of the research is focused on studying and treating its muscular symptoms. On the other hand, despite the significant impact of the neurological symptoms on patients’ quality of life, no drug...
Autores principales: | Eltahir, Mougina K., Nakamori, Masayuki, Hattori, Satoshi, Kimura, Takashi, Mochizuki, Hideki, Nagano, Seiichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249217/ https://www.ncbi.nlm.nih.gov/pubmed/35776705 http://dx.doi.org/10.1371/journal.pone.0269683 |
Ejemplares similares
-
Cellular Senescence and Aging in Myotonic Dystrophy
por: Hasuike, Yuhei, et al.
Publicado: (2022) -
Expanded CUG Repeat RNA Induces Premature Senescence in Myotonic Dystrophy Model Cells
por: Hasuike, Yuhei, et al.
Publicado: (2022) -
Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy
por: Nakamori, Masayuki, et al.
Publicado: (2015) -
Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1
por: Nakamori, Masayuki, et al.
Publicado: (2022) -
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
por: Wheeler, Thurman M., et al.
Publicado: (2012)